Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Improved Accuracy and Speed for Disease Research, Two Genomic Companies Integrate Kits and Software to Enable Deep Exploration of Epigenetic Data | ||
By: Nasdaq / GlobeNewswire - 12 Dec 2018 | Back to overview list |
|
OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments. OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions. Active Motif customers will now be able to rapidly interpret their data with ROSALIND’s identification of the significant peaks and known or de novo binding motifs, as well as a functional enrichment analysis based on “close-by genes” using over 20 knowledgebases like GO, COSMIC, WikiPathways, MSigDB, Pfam, Interpro, and more. Scientists and researchers can then share their experiment using a ROSALIND collaborative space to virtually work alongside colleagues and explore the results without having to exchange their files. “Combining the simplicity of our kits with a straightforward online analysis solution allows even beginners to complete an entire ChIP-Seq experiment with ease,” says Ted DeFrank, CEO of Active Motif. “It is our hope that offering a way to analyze ChIP-Seq data with speed and improved accuracy will enable users to publish new findings much more quickly.” “Accelerating discoveries in Epigenetics is critical for drug discovery and disease research,” says Tim Wesselman, CEO of OnRamp BioInformatics. “We’re excited to partner with Active Motif to empower scientists who use their high-quality kits and antibodies with an intuitive ROSALIND analysis, so they can focus on their insights and discoveries, while saving time and removing the frustration that comes with trying to generate them.” About OnRamp BioInformatics About Active Motif A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9b702d01-ddfd-4ca1-964f-fcaaaee88986 Cassandra Wesselman
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |